Associated Papers
Frequencies of CYP2C9 polymorphisms in a Syrian cohort.
Aldiban W et al.
Bmc Genomics, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
35181665 (PubMed )
Supplement: 41525_2022_283_MOESM4_ESM.xlsx › Novel_Previously_described_var.
Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population.
Wang D et al.
Frontiers in Cardiovascular Medicine, 2022
Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population.
Zhao FL et al.
Frontiers in Pharmacology, 2022
Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals.
Kumondai M et al.
Journal of Personalized Medicine, 2021
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.
Shirasaka Y et al.
The Pharmacogenomics Journal, 2016
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Select a paper to view details